Fifty patients were evaluated for serum total PSA (Prostate Specific Antigen), free PSA (f-PSA), free/total PSA ratio (fit PSA ratio) and TPS TM (Tissue Polypeptide Specific Antigen). Fifty patients were clinically evaluated and categorized into BPH (benign prostatic hypertrophy) and CaP (carcinoma prostate) with twenty-five in each category before the serological examination. Serum total PSA concentration is elevated in 80% of BPH cases while it was elevated in all cases of CaP. With total PSA > 10ngl mL, fit PSA ratio was not applicable. For TPS TM, a cell proliferation marker these values were 32% and 92% respectively. The advanced cases of CaP were reflected by the pronounced elevations of PSA and TPS TM while fit PSA ratio was much below the cut-off limit (cut-off limit = 0.14). The data suggest that whentotal PSA concentration < 10nglmL, f/t PSA ratio plays a very important role in discriminating BPH and CaR However, TPS TM can be used as a valuable adjunct in diagnosis and follow-up of prostate cancer patients, especially in differentiating benign from malignant cases.
INTRODUCTION
The first tumor marker for carcinoma prostate (CAP) was acid phosphatase (1). The search for a more sensitive and specific tumor marker for CaP led to the discovery of Prostate Specific Antigen (PSA). The determination of PSA in CaP/benign prostatic hypertrophy (BPH) has improved, if not revolutionized the diagnosis and follow-up in patients affected by thic disease. PSA is a functional product secreted by the normal prostatic epithelium to lyse the seminal coagulum. PSA functions at the highest in all facets of detection, staging, prognosis, follow-up and performance characteristics(2,3). However, since this marker has limited predictive value, further search has led to the discovery of vadous forms of PSA (3). In circulation, PSA is found in either free (unbound) or complexed (bound) form. The level of free (f), bound and total (t) PSA in serum is very Author for correspondence: Dr. Anitha, D. at the above address useful as an aid to discriminate between benign and malignant forms of prostate (4). A very small percentage of PSA is in the free form while the remaining fraction is complexed to Antichymotrypsin (ACT), 82 macroglobulin (AMG) or Protein C Inhibitor (PCI). Malignant prostate cells show synthesis of ACT along with PSA and thus release ACT bound PSA into blood (5), as a result of which the fraction of fPSA is decreased in comparison to tPSA in CaP patients. According to population surveys it has been shown that f/tPSA ratio has a cut-off value of 0.14 (6). However, the ratio in case of BPH is either normal or elevated than the cut off value.
Tissue Polypeptide Specific Antigen (TPS TM) is proposed as an indicator of tumor proliferation rather than tumor burden. TPS TM was identified long ago in human carcinoma and cell lines by the use of antibodies (7). These antibodies have been shown to stain cytoskeletal intermediate filaments pertaining to cytokeratin 8, 18 & 19 (8) . TPS TM is measured by an in vitro monoclonal immunoassay synthesized during the late S-and G 2-phase of the cell cycle and is released immediateiy after the mitosis. During the process of the apoptotic cell death, which can occur in combination with aggressive tumor with a high proliferation rate, also results in release of protein fragments of cytokeratin 18 recognized by antibodies (9-11). When TPS TM is used in combination with PSA, it improves the decision-making in differentiation and follow up of patients with benign/malignant prostate disease (12).
In this study attempts have been made to analyze a set of parameters in correlation with clinical evaluation to assist in the diagnosis of CaP and also to discriminate CaP from BPH
MATERIALS AND METHODS
Prior to the collection of blood to obtain serum, patients were evaluated in the urology out patient department. The detailed clinical evaluation included ultrasound/CT.Scan and histopathological examination. For the purpose of control samples, blood from the blood bank donors was collected. Subjects with hypertension, tuberculosis, renal infection, generalized infection and patients who were under therapy were excluded from the study. Twenty-five patients in the age group of 40 to 60 years were selected for the study under each category. Twenty-five healthy individuals of the same age were selected to serve as control group.
The serum collected was used to evaluate t-PSA, f-PSA and TPS TM. PSA was measured using Can Ag| PSA EIA Kit [Can Ag, Sweden] . This kit is ~ntended to use for tPSA. The cut-off upper limit was 3.8 ng/mL. Free PSA was measured using Can Ag| Free PSA EIA Kit [Can Ag, Sweden]. The cutoff upper limit was 1.3ng/mL The fit PSA ratio was calculated from the values obtained from tPSA and fPSA. The cut-off limit for fit PSA ratio was 0.14 based on population surveys (6). TPS TM was measured using TPS TM ELISA Kit [IDL Biotech, Sweden] . The cut-off upper limit was 140 U/L. The data was analyzed using independent 't' test and presented as mean + S.D. The statistical significance of difference between mean values was determined by the 't' test f~r equality of means.
RESULTS
Group I showed that 12% of healthy individuals had tPSA values >3.8 ng/ml with no clinical manifestations of either BPH/CaP. Group II showed that 80% of BPH patients had tPSA values >3.8 ng/ml while all caP cases showed elevations beyond 3.8 ng/ml for tPSA When the values were compared, groups II and group III were shown to be statistically significant. Group I showed that 20% of patients had elevations of f-PSA while 40% and 32% of groups II & III patients respectively had elevations of f-PSA. However, when group II and group III were compared with each other it was found that the value was statistically significant.
The fit PSA ratio was found to be elevated in 16% of cases in group I while 36% & 4% of cases showed elevations in group I & II respectively. The fit PSA ratio showed 68 % agreement with a kappa coefficient of 0.3377 with a 'p' value > 0.05 in case of BPH patients while it showed 96% agreement in CaP patients. The fit PSA ratio showed 100% sensitivity and 45% specificity with a positive predictive value (PPV) of 50% and a negative predictive value (NPV) of 100%. This was calculated in those patients who had total PSA concentrations < 10 ng/mL, since the decision-making was critical in such patients. At total PSA concentrations > 10 ng/mL, the f/t PSA ratio is not applicable (because at total PSA > 10 ng/mL, the ratio tends to fall below the cutoff limit).
The TPS TM was found to be elevated in 8% of cases in group I while 32% & 92% of oases in group II & group III showed elevated levels respectively. The 'p' value was ascertained to be ~>0.1 in group II and it was < 0.001 in group III when compared with group I. But the groups II & III were found to be statistically significant when compared with each other. However, when both tPSA & TPS TM were combined 28% & 92% of cases showed elevations in groups II & III respectively. *PPV -Positive predictive value; ** NPV -Negative
DISCUSSION
The early detection of CaP affords a potential cure, which underscores the importance of an early biochemical indicator (3). In our study, tPSA was found to be elevated in 100% of patients with CaP whereas in BPH patients this marker was elevated in 80%, which is very similar to observations made by others (11, 12) .
The CaP patient's prostate gland expressed ACT along with PSA in the circulation, as a result of which, majority of the PSA secreted was found predictive value in the bound form and the fraction of fPSA was decreased. When fPSAis compared with tPSA, the ratio obtained should be ideally below 0.14 (the cut-off limit). However, in case of BPH patients the fit PSA ratio could be either normal or increased. The fit PSA ratio was elevated in 36% of patients with BPH and 4% of patients with CaP. The decision-making was very critical at t-PSA concentration <10 ng/mL since CaP would go unnoticed, if not scrutinized carefully. This was the reason for us to categorize these patients further into Group (a) patients with t-PSA concentration <10 ng/mL; Gr_oup (b) patients with tPSA concentration >10 ng/mL. The results of this study are in accordance with the report which compares BPH and CaP patients with tPSA concentration < 10 ng/mL (13) (14) (15) .
In our study TPS TM was found to be elevated in 32% of patients with BPH and in 92% of patients with CaP. The levels were compared with that of PSA to determine the usefulness when both the markers were used in combination. When both were used, TPS TM + PSA showed sensitivity of 72% in diagnosing CaP and the specificity of 80% in excluding BPH. The PPV was calculated to be 50.6% and NPV was 78%. This study is in accordance with other studies carried out. (16, 17) .
C o n c l u s i o n
In view of the above repo~ts it can be concluded that the tPSA has great significance in differentiating BPH and CaP with an overall accuracy of 60% However, the FIT PSA ratio improved the specificity of PSA without impairing the sensitivity in diagnosing CaP. It can be concluded that F/T PSA ratio can improve the decision-making in discriminating BPH and CaP especially in cases with t-PSA < 10 ng/mL. Perhaps, the combination of TPS TM + PSA is most useful in diagnosing CaP and in differentiating CaP and BP.H in all ranges of t-PSA concentration.
